



Market Announcements Platform
Australian Securities Exchange
Sydney NSW 2000

PHYLOGICA TO BE FEATURED AT PERTH SMALL CAP SHOWCASE 2012

PERTH, AUSTRALIA: June 6, 2012 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, is pleased to announce that on Tuesday, 12 June 2012, the Company will be participating in the Perth Small Cap Showcase 2012.

Shareholders wishing to attend may contact the company and a copy of the presentation by Dr Hopkins will be made available on the Company's website.

For further information, please contact:

Nick Woolf
CFO & VP, Corporate Development
Tel: +61 417 986 005
nwoolf@phylogica.com

Rudi Michelson
Monsoon Communications
Tel + 61 3 9620 3333

About Phylogica

Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia, and Oxford, UK, with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics. The Company was incorporated in 2001 as a spin out from the Telethon Institute for Child Health Research (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). The Company's drug discovery platform is based on its proprietary Phylomer[®] libraries of natural peptides, which have been optimised by evolutionary selection to have stable drug-like structures. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer[®] libraries and proprietary screening technologies. Its current partners include Roche, MedImmune (the worldwide biologics arm of AstraZeneca), Pfizer and Janssen (the pharmaceutical arm of Johnson & Johnson).